MarketPeel
Insider Trading Intelligence
MB

Mark E. Bunnage

VRTX
EVP, CHIEF SCIENTIFIC OFFICER · VERTEX PHARMACEUTICALS INC / MA · CIK 0002100735
FILING MIX · LIFETIME10%/90%
BUYS
1
SELLS
9
TOTAL VALUE
$5.46M
COMPANIES
1
ACTIVE SINCE
Feb 2026
HOLDINGS NOW
7,284
AVG SELL PX
$479.20
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 12 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Mark E. Bunnage, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+25.00%+1.43%-0.08%+1.51%+1.58%
14d4+25.00%+1.91%-0.70%+2.61%+3.07%
30d4+75.00%-4.02%-5.42%+1.40%+0.68%
60d4+100.00%-7.65%+2.40%-10.05%-10.73%
90d4+100.00%-7.10%+7.85%-13.97%-15.26%
180d4(4 pending)
1y4(4 pending)
2y4(4 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VRTX · 7,284 shares · as of May 15, 2026
03,7347,46811,20114,935SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2026
2026
FLOW · 1 buys / 9 sellsCOVERAGE · 2 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
33$453.45$15.0K7,284May 15, 2026May 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
620$486.35$301.5K7,284Feb 25, 2026Feb 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Scientific Officer
582$485.11$282.3K7,904Feb 24, 2026Feb 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
1,182$473.68$559.9K8,486Feb 18, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Scientific Officer
1,110$483.75$537.0K12,105Feb 17, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,437$489.46$1.19M9,668Feb 17, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
PURCHASEGRANT
Stock grant
2,58413,215Feb 17, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Scientific Officer
2,283$487.76$1.11M10,631Feb 13, 2026Feb 18, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,021$460.43$930.5K12,914Feb 11, 2026Feb 12, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Scientific Officer
1,127$468.41$527.9K14,935Feb 10, 2026Feb 12, 2026View →
Other insiders · VRTX
Loading peer insiders…
About this filer
CIK 0002100735
ROLE
EVP, Chief Scientific Officer
PRIMARY
VRTX
COMPANIES
1
ACTIVE SINCE
Feb 2026
MARKETPEEL · /INSIDER/0002100735DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback